A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies (Q43973641)

28 November 2017

title

A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies (English)

1 reference

28 November 2017

Wenting Liao

1

1 reference

28 November 2017

Qiuli Chen

2

1 reference

28 November 2017

Jie Cao

3

1 reference

28 November 2017

Guangguo Tan

4

1 reference

28 November 2017

Zhenyu Zhu

5

1 reference

28 November 2017

Huaqun Zhang

6

1 reference

28 November 2017

Yifeng Chai

7

1 reference

28 November 2017

Wei Pan

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

11 February 2012

1 reference

28 November 2017

1 reference

28 November 2017

volume

30

1 reference

28 November 2017

issue

14

1 reference

28 November 2017

page(s)

2453-2461

1 reference

What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Structural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Full-length HIV-1 Tat protein necessary for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat induces biochemical changes in the serum of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

The preventive phase I trial with the HIV-1 Tat-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.055

10.1016/J.VACCINE.2012.01.055

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference